+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone

Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone

Seminars in Oncology 30(2): 270-274

Twelve patients with Waldenstrom's macroglobulinemia (WM) underwent treatment with the nonmyelosuppressive combination regimen BLT-D: clarithomycin (Biaxin [BXN], Abbott Laboratories, Abbott Park, IL) 500 mg orally twice daily, low-dose thalidomide (THAL) 50 mg orally escalated to 200 mg daily, and dexamethasone (DXM) 40 mg orally once weekly all with modification for toxicity. Omeprazole (correction of omepraxole) 20 mgm orally twice daily for 2 days with the DXM, and enteric-coated aspirin 81 mg orally daily were also administered. Twelve patients have been evaluated. All had previously received at least one purine analogue or alkylating agent. Five had a reduction in either leukocytes and/or platelets prior to treatment, of which three were disease-related. Median age was 62 years. All patients received a minimum of 6 weeks of therapy. Of the 12 patients, 10 had a significant response (83%) consisting of three near complete, three major, four partial, and two minor responses. Four of five had restoration of reduced blood counts. Two with minor responses did not receive sufficient dose escalation due to toxicity. Median time on therapy was 7 months (range, 3 to 28 months). Patients were removed from therapy primarily due to neurotoxicity. Drug resistance occurred in three patients, with one transformation to large cell lymphoma. Toxicity was as follows: gastrointestinal (primarily constipation), 42%; neurological, 100%; endocrine, 42%, and thrombotic, 8%. Most toxicities were World Health Organization (WHO) grade 1 or 2; however, neurological toxicity was more prominent and severe in WM patients than in myeloma. BLT-D is effective in WM. Because of its toxicity, predominantly neurological, BLT-D may best serve as an induction regimen or to "rescue" patients with refractory disease or disease-related low counts.

(PDF same-day service: $19.90)

Accession: 035980647

Download citation: RISBibTeXText

PMID: 12720151

DOI: 10.1053/sonc.2003.50044

Related references

BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia. Leukemia & Lymphoma 43(9): 1777-1782, 2003

Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Seminars in Oncology 30(2): 265-269, 2003

Clarithromycin, Thalidomide and Dexamethasone for the Treatment of Waldenstroms Macroglobulinemia. Blood 100(11): Abstract No 5099, November 16, 2002

Successful treatment with rituximab and thalidomide of POEMS syndrome associated with Waldenstrom macroglobulinemia. Journal of the Neurological Sciences 297(1-2): 101-104, 2010

Advances in the biology and treatment of Waldenström's macroglobulinemia: a report from the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden. Clinical Lymphoma & Myeloma 9(1): 10-15, 2009

Non-myelosuppressive therapy with BLT-D , low dose thalidomide and dexamethasone is highly active in Waldenstroms macroglobulinemia and myeloma. Blood 96(11 Part 1): 167a, November 16, 2000

Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma. British Journal of Haematology 143(3): 349-354, 2008

Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. Journal of Clinical Oncology 25(22): 3344-3349, 2007

Clarithromycin, dexamethasone and low dose thalidomide is effective therapy in relapsed/refractory myeloma and useful in patients with cytopenias. British Journal of Haematology 125(Suppl 1): 20, April, 2004

Severe peripheral neuropathy following carfilzomib, rituximab, and dexamethasone for initial treatment of Waldenström's macroglobulinemia. Annals of Hematology 95(2): 347-348, 2016

Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood 122(19): 3276-3282, 2014

Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 112(12): 4452-4457, 2008

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study. Blood 126(11): 1392-1394, 2015

Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. Blood 124(4): 503-510, 2014

Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology 30(2): 121-126, 2003